EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

Danilo Giffoni de Mello Morais Mata iD, Rossanna C Pezo, Kelvin K W Chan, Ines Menjak, Andrea Eisen, Maureen Trudeau iD

Current Oncology · 25.12.2024 · 32 (1) · 6

DOI: 10.3390/curroncol32010006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Current Oncology, online erschienen am 25.12.2024. Verfasst von Danilo Giffoni de Mello Morais Mata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: Cyclophosphamide, Breast Neoplasms, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC).

Methods

Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia.

Results

With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, p = 0.021) and HR 0.71 (0.56–0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT.

Conclusion

Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideBreast NeoplasmsDocetaxelAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesHumansFemaleMiddle AgedRetrospective StudiesChemotherapy, AdjuvantTaxoidsAdultErb-b2 Receptor Tyrosine KinasesAged

Stichwörter der Autor:innen

adjuvantdoxorubicinendocrine (hormone) receptorepirubicinhuman epidermal growth factor receptor 2 negativeinvasive breast carcinomapaclitaxel

Substanzen

CyclophosphamideDocetaxelAnthracyclinesTaxoidsErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada.
  • Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada.
  • ICES Western, London, ON N6A 5W9, Canada.
  • Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
  • Cancer Program, ICES, Toronto, ON M4N 3M5, Canada.

ORCID-Profile: Danilo Giffoni de Mello Morais Mata, Maureen Trudeau

Zitieren

APA

Giffoni de Mello Morais Mata, D., Pezo, R. C., Chan, K. K. W., Menjak, I., Eisen, A., & Trudeau, M. (2024). A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology, 32(1), 6. https://doi.org/10.3390/curroncol32010006

Vancouver

Giffoni de Mello Morais Mata D, Pezo RC, Chan KKW, Menjak I, Eisen A, Trudeau M. A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology. 2024;32(1):6. doi:10.3390/curroncol32010006

BibTeX
@article{GiffonideMelloMoraisMata2024,
  author = {Giffoni de Mello Morais Mata, Danilo and Pezo, Rossanna C and Chan, Kelvin K W and Menjak, Ines and Eisen, Andrea and Trudeau, Maureen},
  title = {A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer},
  journal = {Current Oncology},
  year = {2024},
  volume = {32},
  number = {1},
  pages = {6},
  doi = {10.3390/curroncol32010006}
}
Kostenlos starten →